Precigen (PGEN) Research & Development (2012 - 2026)
Precigen (PGEN) reported Research & Development of $5.6 million for Q1 2026, down 46.19% year-over-year from $10.5 million in Q1 2025, and down 19.34% quarter-over-quarter from $7.0 million in Q4 2025.
Precigen (PGEN) Research & Development (2012 - 2026) Analysis & Trends
Precigen (PGEN) has 15 years of Research & Development data on file, last reported at $5.6 million in Q1 2026.
- Research & Development for Q1 2026 came in at $5.6 million, down 46.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $36.5 million (down 25.98% YoY), and the FY2025 annual result was $41.3 million, down 22.12% from the prior year.
- Research & Development declined to $5.6 million in Q1 2026 per PGEN's latest filing, from $7.0 million in the prior quarter.
- Over five years, Research & Development peaked at $15.7 million in Q2 2024 and troughed at $5.6 million in Q1 2026.
- A 5-year average of $11.5 million and a median of $11.8 million in 2022 frame the typical range for Research & Development.
- The sharpest annual moves came in 2024 and 2026: Research & Development surged 32.16% in 2024, then plunged 46.19% in 2026.
- A 5-year view of Research & Development shows it stood at $10.8 million in 2022, then rose by 20.39% to $13.0 million in 2023, then fell by 9.51% to $11.8 million in 2024, then tumbled by 40.55% to $7.0 million in 2025, then slipped by 19.34% to $5.6 million in 2026.
- Business Quant data shows PGEN's Research & Development at $5.6 million in Q1 2026, $7.0 million in Q4 2025, and $12.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 1.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -2.30 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -58.00 Mn |
| 10 | Precigen | 1.27 Bn | 1.27 Bn | 20.69 Mn | 5.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.64 Mn |
| Dec 31, 2025 | 6.99 Mn |
| Sep 30, 2025 | 12.38 Mn |
| Jun 30, 2025 | 11.49 Mn |
| Mar 31, 2025 | 10.48 Mn |
| Dec 31, 2024 | 11.76 Mn |
| Sep 30, 2024 | 11.37 Mn |
| Jun 30, 2024 | 15.69 Mn |
| Mar 31, 2024 | 14.25 Mn |
| Dec 31, 2023 | 12.99 Mn |
| Sep 30, 2023 | 11.58 Mn |
| Jun 30, 2023 | 11.87 Mn |
| Mar 31, 2023 | 12.16 Mn |
| Dec 31, 2022 | 10.79 Mn |
| Sep 30, 2022 | 12.62 Mn |
| Jun 30, 2022 | 11.95 Mn |
| Mar 31, 2022 | 11.80 Mn |
| Dec 31, 2021 | 12.18 Mn |
| Sep 30, 2021 | 12.43 Mn |
| Jun 30, 2021 | 13.18 Mn |